George Painter

InstitutionEmory University
AddressAtlanta
Georgia
United States
vCardDownload vCard
    Publication Timeline
    COVID-19 publications
    Bar chart showing 7 Covid-19 publications, with a maximum of 1 publications in April 2020 and February 2021 and March 2021 and June 2021 and July 2021 and August 2021 and October 2021
    All Publications
    Bar chart showing 28 publications over 12 distinct years, with a maximum of 6 publications in 2021
    These graphs show COVID-19 publications by month since August 2019 and all publications written by authors of COVID-19 publications over the past 30 years.

    To see the data from both graphs as text, click here.
    Publication Field Summary
    This graph shows the number and percent of publications by field. Fields are based on how the National Library of Medicine (NLM) classifies the publications' journals and might not represent the specific topics of the publications. Note that an individual publication can be assigned to more than one field. As a result, the publication counts in this graph might add up to more than the number of publications the person has written. To see the data as text, click here.
    Publication List
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications.
    Sort By:     Newest   |   Oldest   |   Most Cited   |   Most Discussed
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Troth S, Butterton J, DeAnda CS, Escobar P, Grobler J, Hazuda D, Painter G. Letter to the Editor in Response to Zhou et al. J Infect Dis. 2021 10 28; 224(8):1442-1443. PMID: 34251432.
      Citations: 1     Fields:    
    2. Holman W, Holman W, McIntosh S, Painter W, Painter G, Bush J, Cohen O. Accelerated first-in-human clinical trial of EIDD-2801/MK-4482 (molnupiravir), a ribonucleoside analog with potent antiviral activity against SARS-CoV-2. Trials. 2021 Aug 23; 22(1):561. PMID: 34425873.
      Citations:    Fields:    Translation:Humans
    3. Citations: 2     Fields:    Translation:Humans
    4. Painter GR, Natchus MG, Cohen O, Holman W, Painter WP. Developing a direct acting, orally available antiviral agent in a pandemic: the evolution of molnupiravir as a potential treatment for COVID-19. Curr Opin Virol. 2021 10; 50:17-22. PMID: 34271264.
      Citations: 5     Fields:    Translation:Humans
    5. Painter WP, Holman W, Bush JA, Almazedi F, Malik H, Eraut NCJE, Morin MJ, Szewczyk LJ, Painter GR. Human Safety, Tolerability, and Pharmacokinetics of Molnupiravir, a Novel Broad-Spectrum Oral Antiviral Agent with Activity Against SARS-CoV-2. Antimicrob Agents Chemother. 2021 Mar 01. PMID: 33649113.
      Citations: 20     Fields:    
    6. Wahl A, Gralinski LE, Johnson CE, Yao W, Kovarova M, Dinnon KH, Liu H, Madden VJ, Krzystek HM, De C, White KK, Gully K, Schäfer A, Zaman T, Leist SR, Grant PO, Bluemling GR, Kolykhalov AA, Natchus MG, Askin FB, Painter G, Browne EP, Jones CD, Pickles RJ, Baric RS, Garcia JV. SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801. Nature. 2021 03; 591(7850):451-457. PMID: 33561864.
      Citations: 31     Fields:    Translation:HumansAnimalsCellsPHPublic Health
    7. Sheahan TP, Sims AC, Zhou S, Graham RL, Pruijssers AJ, Agostini ML, Leist SR, Schäfer A, Dinnon KH, Stevens LJ, Chappell JD, Lu X, Hughes TM, George AS, Hill CS, Montgomery SA, Brown AJ, Bluemling GR, Natchus MG, Saindane M, Kolykhalov AA, Painter G, Harcourt J, Tamin A, Thornburg NJ, Swanstrom R, Denison MR, Baric RS. An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Sci Transl Med. 2020 04 29; 12(541). PMID: 32253226.
      Citations: 271     Fields:    Translation:HumansAnimalsCellsPHPublic Health
    8. Agostini ML, Pruijssers AJ, Chappell JD, Gribble J, Lu X, Andres EL, Bluemling GR, Lockwood MA, Sheahan TP, Sims AC, Natchus MG, Saindane M, Kolykhalov AA, Painter GR, Baric RS, Denison MR. Small-Molecule Antiviral ß-d-N4-Hydroxycytidine Inhibits a Proofreading-Intact Coronavirus with a High Genetic Barrier to Resistance. J Virol. 2019 12 15; 93(24). PMID: 31578288.
      Citations: 57     Fields:    Translation:AnimalsCells